Değer202320242025TTMSatış/genel/idari giderler336.6 M560.7 M456.4 M435.1 MAraştırma ve geliştirme————Faaliyet karı63.1 M-161.9 M-872.6 M-355.9 MFaaliyet Dışı Gelir, Toplam7.7 M10.6 M-19.1 M-3.3 MFaiz gideri (aktifleştirilmiş faizler düşüldükten sonra)69.8 M———Faaliyet Dışı Gelir (Faiz Giderleri Hariç)-69 M-10.7 M-27 M-11.7 MOlağandışı gelirler/giderler6.9 M21.3 M7.9 M8.4 MVergi öncesi kar1.1 M-275 M-983 M-447.3 MKazançlardaki özsermayeler————Vergiler4.5 M-3.5 M3.2 M-400 KKontrol gücü olmayan/azınlık payı————Vergi sonrası diğer gelirler/giderler1 M-9.3 M-4.5 M-4.6 MDurdurulan faaliyetler öncesi net kar-3.4 M-271.5 M-986.2 M-446.9 MDurdurulan faaliyetler—-57 M0—Net kar-3.4 M-328.5 M-986.2 M-446.9 MSeyreltme ayarlaması————İmtiyazlı temettüler————Adi hisse senedi sahiplerine düşen seyreltilmiş net kar-3.4 M-328.5 M-986.2 M-446.9 MTemel hisse başına kazanç (Temel EPS)-0.04-3.67-10.81-4.81Seyreltilmiş hisse başına kazanç (Seyreltilmiş EPS)-0.04-3.67-10.81-4.81Dolaşımdaki ortalama adi hisse senedi sayısı88.8 M89.5 M——Dolaşımdaki seyreltilmiş hisse senedi sayısı88.8 M89.5 M——FAVÖK159.5 M-75 M-794.6 M-277.6 MFVÖK63.1 M-161.9 M-872.6 M-355.9 MGelir maliyeti2.59 B2.16 B2.22 B2.2 BSatılan malların diğer maliyeti2.59 B2.16 B2.22 B2.2 BAmortisman ve itfa (nakit akışı)96.4 M86.9 M78 M78.3 M
Fortrea Holdings Inc. - Common Stock
Fortrea Holdings Inc. is an American contract research organization organized in Delaware and headquartered in Durham, North Carolina with operations in 90 countries. Its customers are primarily in the pharmaceutical, biotechnology, and medical device industries.
Its primary business is handling all aspects of clinical trials including phase I through IV clinical trial management, clinical pharmacology, and post-approval services. It handles regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. It focuses on oncology, central nervous system and neurodegenerative, rare diseases, and cell and gene therapies. In the five years ending in 2023, it conducted more than 5,850 clinical trials involving over 1 million subjects. It also conducted over 600 studies for medical device companies.
The company is one of the largest participants in the international primate trade and has been criticized for its animal testing practices, most specifically animal testing on non-human primates.